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Objective: There are pathophysiologic similarities between calcification and athero-
sclerosis. We wished to determine whether risk factors for atherosclerosis were
linked to bioprosthetic valve calcification and dysfunction.
Methods: We performed a retrospective cohort study on 144 patients at a single
institution who had bioprosthetic aortic or mitral valves removed, serum cholesterol
levels recorded, and valve calcification assessed on the basis of hematoxylin and
eosin staining and radiography of the valve. We also performed case-control
analysis of a group of 66 patients whose tissue valves were explanted and compared
them with an age- and position-matched group of 66 patients with similar duration
of implantation. We also compared mean serum cholesterol levels.
Results: In the retrospective cohort study cholesterol (P  .035), younger age at
implantation (P  .014), and coronary artery disease (P  .017) were linked to
calcification of the valve by means of univariate analysis. In stepwise multiple
regression analysis only the mean serum cholesterol level was linked to calcification
(P  .02). Sex, hypertension, smoking, diabetes, and implant position were not
linked to calcification. In the case-control analysis the mean serum cholesterol level
of the explanted valve group was significantly higher (189 vs 163 mg/dL, P 
.0001) than that of the group whose valves did not require explantation. For those
whose serum cholesterol levels were greater than 200 mg/dL, the odds ratio was 3.9
(95% confidence interval, 1.7-8.9) for valve explantation.
Conclusions: Increased serum cholesterol level may be a risk factor for bioprosthetic
valve calcification requiring explantation.
Bioprosthetic valve replacement has improved the outcomes of pa-tients with valvular heart disease. Tissue valves have central flowand a high freedom from thrombus formation, usually without theneed for anticoagulation. However, most tissue valves are alteredbiologic materials that undergo degenerative processes.1,2
A study of the causes of valve failure necessitating reoperation at our institution
has reported that sterile degeneration, or primary tissue failure, accounted for 74%
of bioprosthetic valve failures.3 Primary tissue failure was most often related to
calcification of the tissue cusps. Calcification was present in 86% of patients, and
cuspal defects in 79% of bioprosthetic valves were removed for primary tissue
failure. Seventy-five percent of valves with degenerative failure had both calcifica-
tion and tears.
No medical therapy, as of yet, has been demonstrated to be effective in the
prevention of the progression of bioprosthetic calcification. Recently, a compelling
argument has been espoused demonstrating the similarities between calcific aortic
sclerosis in the native valve and atherosclerosis.4,5 Chronic inflammatory changes in
the leaflet, including cellular infiltration of macrophages and T lymphocytes and
lipoprotein deposition in apposition to areas of calcification, has prompted investi-
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gation as to whether medical therapy can be applied to slow
the progression of valvular failure.
Several studies have documented a correlation between
lipids and calcification. Pohle and colleagues6 have docu-
mented that both coronary calcification and aortic valve
calcification progress more rapidly in subjects with low-
density lipoprotein (LDL) levels of greater than 130 mg/dL.
Callister and associates7 demonstrated that patients who
reduced their cholesterol levels with lipid-lowering agents
significantly reduced the progression of coronary calcifica-
tion. In another study the risk factor that most significantly
correlated with coronary calcification was LDL levels, and
this was stronger than age, male sex, blood pressure, fasting
insulin level, or smoking.8 Native aortic valve calcium
accumulation, as assessed by means of electron beam com-
puted tomography, is diminished by statin use.9
We hypothesized that serum cholesterol levels might be
associated with increasing bioprosthetic valve calcification,
as assessed by means of a retrospective cohort study. We
also questioned whether increased serum cholesterol levels
are associated with a higher incidence of valve explantation,
as assessed by means of a case-control study.
Methods
For the cohort study, as well as for the case-control analysis, the
Brigham & Women’s Hospital Institutional Review Board ap-
proved the study. Exclusion criteria included the following: (1)
lack of serum cholesterol measurement; (2) a bioprosthetic valve
in the tricuspid position; or (3) rapid valvular failure (1 year,
deemed to be due to a technical cause). No patients were known to
have renal failure or secondary hyperparathyroidism. Total serum
cholesterol levels were available in all study patients, and our
laboratory’s normal range is 140 to 230 mg/dL. Because patients
had multiple cholesterol measurements while the valve was in
place, the mean serum cholesterol level was obtained by determin-
ing the average in any single year and then averaging together all
years during which the valve remained implanted. Cholesterol
values assayed during a period up to 1 month after cardiac surgery
were discarded. Coronary artery disease was defined by a history
of myocardial infarction, angioplasty, or cardiac catheterization
identifying a greater than 50% stenosis. Diabetes mellitus was
defined by a need for either oral or parenteral hypoglycemic
agents. Hypertension was defined as medical treatment with more
than one antihypertensive agent. Smoking was self-reported, and
patients were divided into former smokers and smokers at the time
of valve implantation.
Historical Cohort
We performed a retrospective cohort study of all patients referred
to our single center over 10 years (1992-2002) for individuals who
had their bioprosthetic aortic or mitral valves removed and who
had serum cholesterol levels (excluding up to 1 month after valve
surgery) measured during the period when the valve was in use.
One hundred forty-four patients met the inclusion and exclusion
criteria. We reviewed the medical records for the pathologic as-
sessment of calcification at the time of explantation. Calcification
was assessed by means of a combination of histologic and radio-
graphic methods. Valves were radiographed for calcium and
stained with hematoxylin and eosin after decalcification of the
tissue for sectioning. A grading scheme of 0 to 4 was reported,
with heavy calcification given a rating of 4 and no calcification
given a rating of 0.
Case-Control Study
We performed a case-control study of patients referred to our
single center over 10 years (1992-2002) for individuals who had
their bioprosthetic aortic or mitral valves removed and who had
serum cholesterol levels measured while the valve was in place.
Control subjects were matched to patients for (1) duration of valve
survival, (2) age of the patient at the time of implantation (within
1-5 years of patient age), and (3) valve position (aortic vs mitral)
by using the Brigham Cardiac Surgery Database. We matched
patients against our computerized prospective database from 1992
onward, using a computerized sorting algorithm that first sorted by
duration of survival (for control subjects) or removal (for patients),
then by age at implantation, and finally by position. Fewer patients
are enrolled in the case-control analysis than in the cohort analysis
because of adequate statistical power with approximately 70 pa-
tients in each group and difficulty in finding adequate control
subjects for all patients. It should be noted that the same patients
in the cohort analysis were used as patients here. Matched control
subjects, however, are a different group of patients and are not
represented in the group of patients in the cohort analysis.
Patients and control subjects were temporally mismatched, on
average, by 6 years because the mean  SD year of birth for the
patients was 1930  1.8 versus 1936  1.7 for control subjects (P
 .001). Thus the age of the patient at implantation is matched, but
patients represent an earlier surgical population. We performed 2
additional analyses to investigate whether this had any effect on
mean cholesterol levels between patients and control subjects.
First, we removed all pairs in which one or both members were
taking statins to remove the confounding effects of these drugs
(data not shown). Second, we reanalyzed patients by matching for
year of operation (thus valves were implanted during the same year
in both patients and control subjects), age of patient at implanta-
tion, and position. This effectively removed any possible con-
founding effects of changing medical-surgical practices, although
it reduced our analyses to 22 patients.
Statistical Analyses
All analyses were carried out with the Statistica software package
(version 5.5, Tulsa, Okla), and P values are reported. For cohort
analyses, we used the nonparametric test of correlation because
calcification was not distributed in a normal manner (Table 1 for
the distribution of calcification). We used the Spearman rank order
coefficient to compare ordered categoric data (eg, calcification)
versus continuous data (eg, serum cholesterol level). To compare
ordered categorical versus dichotomous data (eg, sex), we used the
Wilcoxon rank sum test. All risk factors that had a P value of less
than .10 in the univariate analyses were also analyzed by means of
stepwise multiple regression.
For case-control analysis, groups were examined by using a
2-tailed paired Student t test, and all P values are reported. The
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odds ratio for explantation was calculated for those whose serum
cholesterol levels were greater than 200 mg/dL.
Results
Cohort Analysis
Of the 144 patients who met study inclusion and exclusion
criteria, 82 (57%) were men (Table 1). The mean  SD age
at implantation was 55  12.9 years. Because the valves in
this group were implanted in aggregate from 1984.8  4.4
and because these patients went on to have their valves
explanted, they represent a younger population than those
who are currently receiving tissue valves. The youngest
patient in this series to receive a bioprosthetic valve was 23
years of age, and the oldest was 79 years of age (age at the
time of implantation). The mean valve survival was 10.9 
4.4 years, ranging from 1 year to 21 years. Ninety-seven
(67%) patients had valves placed in the aortic position, and
47 (33%) had valves placed in the mitral position. Coronary
artery disease was present in 69 (48%) patients, diabetes
mellitus was present in 26 (18%) patients, and hypertension
was present in 87 (60%) patients. The mean cholesterol
level of the group (n 144) was 191 42 mg/dL. Eighteen
(13%) patients had their valves removed without any calci-
fication. The distribution of the calcification is shown in
Table 1, and the majority of patients had 1 to 2 calcifi-
cation. This non-Gaussian distribution of calcification led us
to use nonparametric analyses of correlation. Causes of
failure included leaflet tear (91 [63%] patients), degenera-
tion (40 [28%] patients), bacterial endocarditis (5 [3.5%]
patients), and others, including perforation, thrombosis, or
paravalvular leak (8 [5.55] patients combined). Removing
patients with bacterial endocarditis and other causes still
resulted in a significant correlation between calcification
and cholesterol level (r  0.169, P  .04). These causes
might have coexisted with valvular calcification, and this is
in agreement with previous reports from our institution.3
Stepwise multiple regression was performed on all de-
pendent variables with a significance of less than .10 deter-
mined by means of univariate analysis. Thus implant age,
coronary artery disease, average serum cholesterol level,
and diabetes mellitus were used as dependent variables in
predicting calcification. Of the 4 dependent variables, only
average cholesterol level achieved significance (P  .02) in
the multiple regression (Table 2).
Case-Control Analysis
Sixty-six patients met study inclusion and exclusion cri-
teria as patients in the explanted valve group, and 32
(48%) were male (Table 3). The mean  SE age at
implantation was 57.6  1.7 years. The youngest patient
in this series to receive a bioprosthetic valve was 24 years
of age, and the oldest was 79 years of age (age at the time
of implantation). The mean valve survival was 7.3  0.3
years, ranging from 1 year to 9 years. Patient age, dura-
tion of valve survival (or until explantation), and position
were all matched. Forty-three (65%) patients had valves
placed in the aortic position, and 23 (35%) had valves
placed in the mitral position. Coronary artery disease was
present in 33 (50%) patients, diabetes mellitus was
present in 17 (26%) patients, hypertension was present in
42 (64%) patients, and 15 (23%) patients smoked at some
point while their valvular prostheses were in place. The
mean  SD cholesterol level of the explanted patients (n
 66) was 189  40 mg/dL, which was significantly
higher than the value of 163  39 mg/dL in the control
group (P  .0001, Figure 1). The mean serum cholesterol
level is still in the high normal range for North Ameri-
cans, implying that calcification might still occur in the
high normal range, which is consistent with vascular
atherosclerosis. Four (6.1%) patients were taking statins
during the period of valve function versus 12 (18%)
patients in the control group (P  .018). Coronary artery
disease, presence of hypertension, presence of diabetes
mellitus, and smoking status were not significantly dif-
ferent between patients and control subjects (Table 3).
TABLE 1. Cohort analysis
Parameter Mean (SD)
Range (min-max)
or %
Age (y) 55 (12.9) 23-79
n 144 patients Not applicable
Sex 82 male 57%
62 female 43%
Valve survival (y) 10.9 (4.4) 1-21
Valve position 97 aortic 67%
47 mitral 33%
Mean serum
cholesterol
level
191 mg/dL (42) (93-308 mg/dL)
Coronary artery
disease
69 patients 48%
Diabetes 26 patients 18%
Hypertension 87 patients 60%
Statin use 19 patients 13%
Smoker No, 103 patients 72%
Former, 13 patients 9%
Yes, 28 patients 19%
Distribution of 0, 18 patients 13%
calcification 1, 67 patients 46%
2, 34 patients 24%
3, 22 patients 15%
4, 3 patients 2%
Classification of Leaflet tear, 91 patients 63%
valve failure Degeneration, 40 patients 28%
Bacterial endocarditis, 5
patients
3.5%
Other (perforation-
thrombosis or
paravalvular leak), 8
patients
5.5%
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Because patients represent an earlier cohort on average
than control subjects by 6 years, we performed 2 additional
analyses to rule out potential sources of bias. In one sub-
group analysis all patient pairs in which one or both patients
were taking statins were removed from analysis (data not
shown). In another analysis matching was performed by
comparing valves matched and implanted during the same
year (including matched at position and age of patient,
Table 4). The results of both these analyses demonstrate that
cholesterol levels are significantly higher in patients (ex-
planted valve patients) than in control subjects.
We removed patient pairings in which one or both of the
patients were taking statins because these drugs might in-
fluence calcification of the valve. A total of 16 paired groups
TABLE 3. Case-control analysis
Parameter
Control subjects (no failure) Patients (valve failure)
P valueMean (SE, range) Mean (SE, range)
Age at implantation (y) 57.7, (1.7, 21-79) 57.6 (1.7, 24-79) Matched, .29
N 66 patients 66 Matched
Valve follow-up (y) 7.3 (0.3, 1-9) 7.3 (0.3, 1-9) Matched, .47
Valve position 43 aortic (65%) 43 aortic (65%) Matched
23 mitral (35%) 23 mitral (35%)
Sex 27 male (41%) 32 male (48%) .39*
39 female (59%) 34 female (52%)
Cholesterol average 163 (39 sd, 73-314  range,
median  162, mode  163)
189 (40 sd, 103-293 range,
191  median, 175  mode)
2-tailed t test paired for means*†
Diabetes mellitus 11 patients (17%) 17 patients (26%) .13
Hypertensive 41 patients (62%) 42 patients (64%) .29
Statin use 12 patients (18%) 4 patients (6%) .018*†
Coronary artery disease 30 patients (46%) 33 patients (50%) .30
Smoker 14 patients (21%) 15 patients (23%) .936*
Odds ratio for re-replacement,
serum cholesterol 200 mg/dL
Referent 3.9 (95% confidence interval, 1.7-8.9)
Classification of valve failure Not applicable Leaflet tear, 35 patients (53%)
Degeneration, 24 patients (36%)
Bacterial endocarditis, 4 patients
(6.1%)
Paravalvular leak, 1 patient (1.5%)
Other, 2 patients (3%)
*Two-tailed t test.
†Significant at P  .05.
TABLE 2. Significance and correlations of cohort analysis
Spearman correlation,  P value
Calcification vs implant age 0.205 .014*
Calcification vs cholesterol average 0.176 .035*
Calcification vs valve type 0.015 .85
P value, Wilcoxon rank sum test
Calcification vs coronary artery disease .017*
Calcification vs diabetes mellitus .069, trend
Calcification vs aortic-mitral position .367
Calcification vs hypertension .414
Calcification vs smoking .57 (.49)
Calcification vs sex .938
Stepwise multiple regression,  P value
Implant age 0.012 .18
Cholesterol, mean serum 0.189 .02*
Diabetes mellitus 0.09 .30
Coronary artery disease 0.078 .37
*P  .05.
Surgery for Acquired Cardiovascular Disease Farivar and Cohn
972 The Journal of Thoracic and Cardiovascular Surgery ● October 2003
A
CD
(12 control subjects and 4 patients, 32 in total) were re-
moved, and the results were reanalyzed to exclude possible
confounding effects of statins on the results. Patients were
still matched for position of valve and age of implantation,
as well as duration of survival. The mean cholesterol dif-
ference between groups was still highly significant (P 
.00001; patients, 190.8 mg/dL; control subjects, 158.5 mg/
dL). There was no significant difference between groups in
terms of diabetes, hypertension, sex, smoking, or coronary
artery disease.
We also matched patients for the same year of implan-
tation surgery, age at implantation, and valve position (aor-
tic vs mitral). This effectively removed any influence of
possible changing medical-surgical practices through time,
although it limited our analysis to 22 patients (Table 4).
There was still a significant difference in the mean serum
cholesterol levels between patients and control subjects
(187 mg/dL in patients and 155 mg/dL in control subjects;
P  .047, paired t test). Diabetes (P  .059), hypertension
(P  .67), smoking (P  .37), coronary artery disease (P 
.34), and statin use (P .96) were not significantly different
between the 2 subgroups.
For the complete case-control analysis, the odds ratio for
valvular re-replacement in patients whose serum cholesterol
levels were greater than 200 mg/dL was 3.9 (95% confi-
dence interval, 1.7-8.9; Table 3).
Discussion
We have demonstrated for the first time that increasing
serum cholesterol levels are associated with increased bio-
prosthetic valvular calcification. Furthermore, patients who
had their valves explanted had higher serum cholesterol
levels than an age-, duration of survival-, and position-
matched group with unexplanted valves (189 vs 163 mg/dL,
P  .0001). Finally, the odds ratio for valve explantation
and re-replacement was 3.9-fold higher in patients whose
serum cholesterol levels were greater than 200 mg/dL.
It is controversial whether increased serum lipid levels
correlate with the progression of peripheral atherosclerosis,
coronary calcification, and native aortic valve sclero-
sis.4,10,11 Pohle and colleagues6 recently demonstrated that
the rate of change of both coronary and native aortic valve
calcification progresses more rapidly in individuals whose
serum LDL levels are greater than 130 mg/dL. Palta and
coworkers12 also demonstrated that those with a serum
cholesterol level of greater than 200 mg/dL had a rate of
native aortic valve area reduction roughly twice that of
those with a lower cholesterol level (P  .04).
In this cohort study we demonstrate that blood pressure,
sex, and smoking are not linked to tissue valve calcification.
We also demonstrate that coronary calcification is linked to
tissue valve calcification; thus what is harmful to the coro-
nary arteries might be harmful for tissue valves, and what is
protective of the coronary arteries might be protective of the
valves. Prior reports have concluded that tissue valves are
appropriate for patients undergoing mitral valve replace-
ment with coronary artery disease who are more than 60
years of age and for aortic valve replacement in patients
who are more than 70 years of age, irrespective of coronary
artery disease.13 Patients with subcritical coronary disease
who undergo tissue valve replacement might be candidates
for statin therapy.
Younger age has previously been demonstrated as a risk
factor for leaflet failure.1,14-16 In our study younger age was
linked to increasing calcification. Interestingly, the absolute
magnitude of the linear association (  0.205, P  .014)
was similar for younger patients as for cholesterol ( 
0.176, P  .035), implying that the contribution of choles-
terol to calcification of the valve is of a similar importance
as younger age. In our study diabetes, a well-documented
risk factor for atherosclerosis, demonstrated a trend (P 
.069) toward significance in univariate analysis. Patients
were considered diabetic if they were being actively medi-
cally treated, and thus our study might have missed some
patients with untreated diabetes. Also, our limited numbers
might not have had adequate power to elicit the contribu-
tions of these other risk factors for atherosclerosis on val-
vular calcification.
Bellamy and associates,17 however, recently reported
that there was no correlation between the rate of progression
of aortic stenosis with cholesterol levels in 157 patients with
aortic stenosis. Statin therapy, however, was associated with
Figure 1. Plot of mean serum cholesterol levels in the group of
patients whose valves remained intact (control group) versus
those undergoing reoperation (explanted). Groups were matched
for age of patient at implantation, sex, and duration of valve
survival.
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a decreased rate of progression of stenosis-sclerosis of the
aortic valve. In that study the authors confirmed that aortic
stenosis progresses with a reduction in orifice size of ap-
proximately 0.1 cm2/y in patients who are not receiving
statin therapy. For those receiving medical therapy, the
decrease in mean aortic valve area measured was only 0.04
cm2/y, which is approximately half the native rate. Palta and
coworkers12 also documented a near doubling of the rate of
aortic valve area reduction in those whose serum cholesterol
levels were greater than 200 mg/dL. After adjustment for
sex, age, and baseline aortic valve area, statin therapy re-
mained protective, although cholesterol levels during statin
therapy showed no correlation with the progression of aortic
stenosis.17 Both Novaro and colleagues18 and Aronow and
associates19 also reported similar results that statin-treated
groups had a slower rate of aortic stenosis progression.
Shavelle and coworkers9 have documented that patients
receiving statins have a diminished rate of accumulation of
aortic valve calcium, as assessed by means of electron beam
computed tomography, although serum cholesterol levels
were not available. It is an intriguing finding that the effects
of the statins are not solely attributable to lipid-lowering
effects. This is not without precedent because the statins
have been shown to stabilize plaques as part of the benefi-
cial effect in preventing cerebrovascular occlusion and in
reducing inflammation. Currently, there is no information
on the rate of progression of bioprosthetic valve sclerosis
with statin therapy. In our case-control study patients whose
valves were not explanted had a higher incidence of statin
use than those whose valves were explanted (18% vs 6%, P
 .018). Some patients might have been started on statins in
the midst of their valve use. This prompted reanalysis with
all statin pair groups removed. The mean serum cholesterol
level was still higher (190.8 vs 158.5 mg/dL, P  .0001)
when the confounding effects of statins were removed. We
also matched patients so that operations occurred in the
same year while keeping the age of the patient at implan-
tation and position matched and found the explanted valve
group to have a higher serum cholesterol level than the
control subjects (187 vs 155 mg/dL, P  .047).
The correlation of increased cholesterol levels with bio-
prosthetic valvular calcification invites mechanistic specu-
lation.5 Eliminating lipids from tissue valves by means of
ethanol extraction prevents in vivo calcification.20 It is
possible that glutaraldehyde-fixed valves have the appropri-
ate physical characteristics to serve as a nidus for crystalli-
zation. Another potential mechanism is the migration of
cells into the matrix of the valve. Blood-borne progenitor
cells that are capable of differentiating into various lineages
from the marrow might have the ability to deposit matrix,
which can calcify. Additionally, oxidized LDL, which co-
localizes with T lymphocytes and calcium, has been dem-
onstrated in nonrheumatic stenotic aortic valves.21 Older
literature had documented that silicone rubber prostheses in
the Starr-Edwards valve (Edwards Lifesciences, Irvine,
Calif) absorb lipids.22 Ferrans and associates23 had docu-
mented that cholesterol ester crystals were found in porcine
aortic valves that had been implanted in the mitral position
for 8 years.
This study has its limitations. It is retrospective, and the
population for the cohort study is selected for patients who
required reoperation. Patients who did not undergo reopera-
tion were not included in the cohort study, although we
attempt to address this in the case-control study. One could
attempt to address this by using electron beam computed
tomography to measure the progression of calcification over
time in tissue valves. Serum cholesterol values were used
rather than LDL levels. Smoking was self-reported.
In summary, we have shown in a retrospective cohort
and case-control study that cholesterol might contribute to
bioprosthetic valve calcification, which might lead to valve
re-replacement. A randomized prospective clinical trial to
determine whether statins prevent bioprosthetic valve cal-
cium accumulation is warranted.
We thank Dr Fred Schoen of the Department of Pathology at
the Brigham and Women’s Hospital for his review of this manu-
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Discussion
Dr D. Craig Miller (Stanford, Calif). I congratulate Dr Farivar
and Dr Cohn for bringing something to our attention that may
prove to be very important in the future. Certainly it is scientifi-
cally much more appealing than what some of you in the room
may be old enough to remember. In the late 1970s and early 1980s,
Don Magilligan and others were saying, “We’re only going to get
so many heartbeats out of these tissue valves. Why don’t we use
-blockers and slow down their heart rates? Maybe the valves
would last longer.” Those were the old days. This is very prom-
ising and exciting, and it stems from the work being done in the
native aortic valve in elderly patients with aortic sclerosis, where
Emile Moeller at Penn and his vascular biology colleagues think
they are going to take another operation away from us. But don’t
get too paranoid, because the very promising work in elderly
patients with aortic sclerosis does not apply to younger patients
with calcific aortic sclerosis, in whom the valve was originally a
bicuspid valve. In fact, at the American Heart Association meeting
in 2002, Dr Moeller said that the Penn Institutional Review Board
believed it was unethical to randomize large cohorts of patients
with native valve aortic sclerosis. The uncontrolled data had al-
ready proved to their satisfaction that statins retard progression of
aortic sclerosis. I personally do not think that has been proven
conclusively, but that is what Moeller relayed. In any event, there
has been no information, until the material you just heard, about
what happens when patients with bioprosthetic valves are treated
with statins.
This paper was submitted early and actually has already been
revised and accepted for publication in the Journal by Andrew
Wechsler. Tirone David has written an editorial pertaining to this
paper and a similar one from Germany by Nollert and associates
concerning the effects of hyperlipidemia on the durability of the
Hancock pericardial valve. Both papers will be fast-tracked be-
cause the Editor believes this question is important.
Tirone David looked at 635 old Hancock I valves from Stan-
ford implanted in the 1970s and 1980s and observed for 15 years
or more. He could show no adverse impact of hyperlipidemia on
structural valve deterioration (SVD). He then looked at 913 pa-
tients undergoing aortic valve replacement at the Toronto General
Hospital in the 1990s (Hancock II, Carpentier-Edwards pericar-
dial, and Toronto SPV) and again could find no apparent adverse
influence of hyperlipidemia on SVD.
Some of you may have been wondering why the freedom from
SVD curves in Toronto with any kind of tissue valve are so good.
Tirone himself has admitted that maybe it is because in Ontario
almost everybody is already on a statin; maybe they never will see
an effect there in their more recent patients. Another factor per-
taining to the mitral position is that only the very sickest and very
elderly patients undergo mitral valve replacement with a tissue
bioprosthesis; the majority of valves are repaired.
In any event, this is promising work, even though it is just the
first step. I do have one statistical question: When you get down to
the case match controls, exclude the statin matches, and then you
rematch for age, you get to some very small Ns. How does this
affect the reliability of your statistics?
My real question is this: What is the next step? How are we
going to confirm that this is true or not in larger, multicenter
analyses? Tell us where you are headed. In today’s world, at least
in California, it appears that almost everybody is already on
atorvastatin calcium (Lipitor) or some statin, even if they do not
have coronary disease; therefore, how can you ever hope to test
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